Phathom Pharmaceuticals (PHAT) Debt to Equity: 2022-2025
Historic Debt to Equity for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -$0.49.
- Phathom Pharmaceuticals' Debt to Equity rose 47.81% to -$0.49 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.49, marking a year-over-year increase of 47.81%. This contributed to the annual value of -$0.79 for FY2024, which is 58.08% up from last year.
- Phathom Pharmaceuticals' Debt to Equity amounted to -$0.49 in Q3 2025, which was up 3.04% from -$0.51 recorded in Q2 2025.
- In the past 5 years, Phathom Pharmaceuticals' Debt to Equity ranged from a high of $5.56 in Q2 2023 and a low of -$13.20 during Q2 2022.
- Its 3-year average for Debt to Equity is -$0.73, with a median of -$0.79 in 2024.
- Data for Phathom Pharmaceuticals' Debt to Equity shows a peak YoY increase of 142.09% (in 2023) and a maximum YoY decrease of 144.76% (in 2023) over the last 5 years.
- Phathom Pharmaceuticals' Debt to Equity (Quarterly) stood at -$1.27 in 2022, then tumbled by 48.78% to -$1.89 in 2023, then skyrocketed by 58.08% to -$0.79 in 2024, then soared by 47.81% to -$0.49 in 2025.
- Its last three reported values are -$0.49 in Q3 2025, -$0.51 for Q2 2025, and -$0.60 during Q1 2025.